[go: up one dir, main page]

PE20140977A1 - PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND - Google Patents

PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND

Info

Publication number
PE20140977A1
PE20140977A1 PE2014000508A PE2014000508A PE20140977A1 PE 20140977 A1 PE20140977 A1 PE 20140977A1 PE 2014000508 A PE2014000508 A PE 2014000508A PE 2014000508 A PE2014000508 A PE 2014000508A PE 20140977 A1 PE20140977 A1 PE 20140977A1
Authority
PE
Peru
Prior art keywords
acid
hydrocarbon group
pharmaceutical composition
dispersed
formula
Prior art date
Application number
PE2014000508A
Other languages
Spanish (es)
Inventor
Yasuhiro Hiraishi
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140977(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20140977A1 publication Critical patent/PE20140977A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

REFERIDO A UNA PREPARACION SOLIDA QUE COMPRENDE: A) UN INGREDIENTE FARMACEUTICAMENTE ACTIVO DE FORMULA (I); DONDE X E Y SON IGUALES O DIFERENTES Y CADA UNO ES UN ENLACE O UN ESPACIADOR QUE TIENE DE 1 A 20 ATOMOS EN LA CADENA PRINCIPAL, R1 ES UN GRUPO HIDROCARBONADO, R2, R3, Y R4 SON IGUALES O DIFERENTES Y CADA UNO ES UN ATOMO DE H, UN GRUPO HIDROCARBONADO, UN GRUPO TIENILO, ENTRE OTROS, R5 ES H O UN GRUPO HIDROCARBONADO OPCIONALMENTE SUSTITUIDO; B) OXIDO DE TITANIO; C) UN PLASTIFICANTE REPRESENTADO POR LA FORMULA: HOCH2(CH2OCH2)nCH2OH, DONDE n ES UN NUMERO ENTERO DE 2 - 870; Y D) UN ACIDO ORGANICO EN CADENA TAL COMO ACIDO OLEICO, ACIDO ADIPICO, ACIDO SUCCNICO, ACIDO SORBICO, ACIDO FUMARICO, ENTRE OTROS, QUE TIENE UN pH DE 6,0 O MENOS CUANDO SE DISUELVE O DISPERSA EN AGUA Y EL CONTENIDO PORCENTUAL DE DICHO ACIDO ES 0,01-50% EN PESOREFERRED TO A SOLID PREPARATION THAT INCLUDES: A) A PHARMACEUTICALLY ACTIVE INGREDIENT OF FORMULA (I); WHERE XEY ARE THE SAME OR DIFFERENT AND EACH ONE IS A LINK OR A SPACER THAT HAS 1 TO 20 ATOMS IN THE MAIN CHAIN, R1 IS A HYDROCARBON GROUP, R2, R3, AND R4 ARE THE SAME OR DIFFERENT AND EACH ONE IS AN ATOM OF H, A HYDROCARBON GROUP, A TIENYL GROUP, AMONG OTHERS, R5 IS H OR AN OPTIONALLY REPLACED HYDROCARBON GROUP; B) TITANIUM OXIDE; C) A PLASTIFIER REPRESENTED BY THE FORMULA: HOCH2 (CH2OCH2) nCH2OH, WHERE n IS AN INTEGRAL NUMBER OF 2 - 870; AND D) AN ORGANIC ACID IN CHAIN SUCH AS OLEIC ACID, ADIPIC ACID, SUCCNIC ACID, SORBIC ACID, FUMARIC ACID, AMONG OTHERS, WHICH HAS A pH OF 6.0 OR LESS WHEN DISPERSED OR DISPERSED IN WATER AND THE CONTENT OF DICHO ACID IS 0.01-50% BY WEIGHT

PE2014000508A 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND PE20140977A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
PE20140977A1 true PE20140977A1 (en) 2014-08-20

Family

ID=41327301

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2011000089A PE20110591A1 (en) 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND
PE2014000933A PE20141585A1 (en) 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-REQUESTED COMPOUND
PE2014000508A PE20140977A1 (en) 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2011000089A PE20110591A1 (en) 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND
PE2014000933A PE20141585A1 (en) 2008-07-28 2009-07-27 PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-REQUESTED COMPOUND

Country Status (29)

Country Link
US (2) US9186411B2 (en)
EP (2) EP2564833B1 (en)
JP (2) JP5295356B2 (en)
KR (1) KR20110042334A (en)
CN (3) CN102164581A (en)
AR (1) AR072842A1 (en)
AU (1) AU2009277443A1 (en)
BR (1) BRPI0916689A2 (en)
CA (2) CA2936400C (en)
CL (1) CL2011000170A1 (en)
CO (1) CO6290638A2 (en)
CR (1) CR20110110A (en)
DO (2) DOP2011000033A (en)
EA (2) EA201170272A1 (en)
EC (1) ECSP11010855A (en)
ES (2) ES2660962T3 (en)
GE (2) GEP20146122B (en)
IL (2) IL210735A0 (en)
MA (1) MA32556B1 (en)
MX (1) MX2011000757A (en)
MY (2) MY169461A (en)
NZ (2) NZ602592A (en)
PE (3) PE20110591A1 (en)
SG (1) SG186685A1 (en)
TW (2) TW201010992A (en)
UA (1) UA103332C2 (en)
UY (1) UY32008A (en)
WO (1) WO2010013823A2 (en)
ZA (1) ZA201101198B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CN110917130A (en) * 2012-06-27 2020-03-27 武田药品工业株式会社 Liquid formulations of amines and organic acids stabilized with salts
AU2013319118B2 (en) 2012-09-19 2016-03-03 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved elution and/or absorbency
WO2014160278A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (en) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 Pyrrole sulfonamide derivative, preparation method and medical application thereof
CN105985278A (en) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 Pyrrole sulfonyl derivatives, preparation method and medicinal application thereof
MA41850A (en) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co NEW PHARMACEUTICAL USES
PH12018500236B1 (en) 2015-07-30 2023-12-06 Takeda Pharmaceuticals Co Tablet
CN105106203B (en) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 Pharmaceutical composition of Vonoprazan fumarate and preparation method thereof
CN105030725B (en) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 Vonoprazan fumarate enteric-coated composition and preparation method thereof
CN105030720B (en) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 vonoprazan fumarate enteric-coated tablet and preparation method thereof
CN107224438B (en) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 Vonoprazan fumarate pharmaceutical composition
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (en) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 Roxithromycin sustained-release pharmaceutical composition
CN106860852A (en) * 2017-02-17 2017-06-20 王清华 A kind of mucus Western medicine for combined treatment stomach trouble
BR112019022142A2 (en) 2017-05-31 2020-05-12 Boehringer Ingelheim International Gmbh PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL DOSAGE FORM UNDERSTANDING (E) -4- (2- (AMINOMETHIL) -3-FLUOROALYLOXY) -N-TERC-BUTYLBENZAMIDE, PROCESS FOR ITS PREPARATION, METHODS FOR TREATMENT AND ITS USES
SG11202000136YA (en) 2017-07-10 2020-02-27 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN108558831B (en) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 Substituted pyrrole-4-alkylamine compound and application thereof
KR102126576B1 (en) 2018-09-19 2020-06-24 주식회사 대웅제약 Manufacturing method for 4-methoxypyrrole derivatives
CN109288722B (en) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 A kind of foundation for color changing and correcting skin tone and preparation method thereof
CN110538153B (en) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 High-stability and quick-release solid preparation and preparation method thereof
KR20230005280A (en) * 2020-04-24 2023-01-09 독토르. 팔크 파르마 게엠베하 Systemic preparation of pyridinone derivatives for celiac disease
CN111973565A (en) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 Vonoprazan fumarate-containing tablet and dissolution rate determination method thereof
CN114053239A (en) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 Voranolasheng fumarate pharmaceutical composition and preparation method thereof
CN111943932B (en) * 2020-08-06 2023-07-14 四川国康药业有限公司 3-pyridine sulfonyl-1-N-hetero pyrrole derivative capable of treating peptic ulcer and preparation method and application thereof
AU2021351536A1 (en) * 2020-10-01 2023-05-04 Imago Biosciences, Inc. Pharmaceutical formulations for treating diseases mediated by kdm1a
CN114853728B (en) * 2022-05-07 2023-11-07 四川制药制剂有限公司 Vonopraz fumarate tablet and preparation method thereof
CN115364065B (en) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 Furanolas fumarate green sheet
CN115944743B (en) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 A vonoprazan fumarate composition and preparation method thereof
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN119970680B (en) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 Colchicine sustained-release micropill and preparation method thereof
CN117462507B (en) * 2023-12-28 2024-03-15 山东齐都药业有限公司 Vonola fumarate crude drug composition and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (en) 1989-07-13 1999-01-06 株式会社科薬 Aqueous solution of stable polymyxin antibiotics
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (en) 1996-03-04 1998-04-03 Synthelabo SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTINE
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (en) 1996-08-07 1998-11-06 Jouveinal Lab TRIMEBUTINE FILM MALEATE TABLET
JP4730985B2 (en) 1997-09-10 2011-07-20 武田薬品工業株式会社 Stabilized pharmaceutical formulation
DE69815003T2 (en) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
US20050004139A1 (en) * 2001-07-30 2005-01-06 Takeshi Inamori Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient
CN1571664A (en) * 2001-10-17 2005-01-26 久光制药株式会社 transdermal formulation
WO2003074076A2 (en) 2002-02-28 2003-09-12 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
NZ535663A (en) 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (en) * 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Delayed pain reliever containing tilidine and a light stabilizer
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
EP1648416A4 (en) 2003-07-18 2012-03-28 Santarus Inc Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
JP2005263788A (en) 2004-02-17 2005-09-29 Sankyo Co Ltd Stabilized pharmaceutical composition containing indoline compound
KR20120064735A (en) 2004-04-01 2012-06-19 아지노모토 가부시키가이샤 Nateglinide-containing preparation
JP2006001912A (en) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd Method for stabilizing protein preparations
EP1803709B1 (en) * 2004-09-30 2013-01-02 Takeda Pharmaceutical Company Limited Proton pump inhibitors
CA2582300A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
WO2007023931A1 (en) 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. Composition for prevention of increase in blood alcohol level
ATE504567T1 (en) * 2005-08-30 2011-04-15 Takeda Pharmaceutical 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5-(HETERO-)ARYL-SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS
JPWO2007074910A1 (en) 2005-12-28 2009-06-04 武田薬品工業株式会社 Controlled release solid formulation
US20100062063A1 (en) * 2006-09-15 2010-03-11 Astellas Pharma Inc. Light-stable solid pharmaceutical composition of ramosetron
JP5074052B2 (en) 2007-02-13 2012-11-14 有限会社愛和ライト Game machine
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009041705A2 (en) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds as proton pump inhibitors
EP2196459B1 (en) 2007-09-28 2016-11-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound
JPWO2009066746A1 (en) 2007-11-22 2011-04-07 国立大学法人 東京大学 Tissue adhesion prevention material and joint contracture prevention material

Also Published As

Publication number Publication date
AU2009277443A1 (en) 2010-02-04
NZ602592A (en) 2014-01-31
ES2660962T3 (en) 2018-03-26
IL228817A0 (en) 2013-12-31
US20110124687A1 (en) 2011-05-26
WO2010013823A2 (en) 2010-02-04
KR20110042334A (en) 2011-04-26
MX2011000757A (en) 2011-02-24
UA103332C2 (en) 2013-10-10
AR072842A1 (en) 2010-09-22
UY32008A (en) 2010-02-26
ES2669592T3 (en) 2018-05-28
TW201010992A (en) 2010-03-16
PE20110591A1 (en) 2011-09-15
TW201431552A (en) 2014-08-16
EP2564833B1 (en) 2017-12-20
ZA201101198B (en) 2012-05-30
JP5295356B2 (en) 2013-09-18
SG186685A1 (en) 2013-01-30
MA32556B1 (en) 2011-08-01
DOP2011000033A (en) 2011-04-15
CN102743330B (en) 2016-03-23
MY156305A (en) 2016-01-29
IL210735A0 (en) 2011-03-31
GEP20146166B (en) 2014-09-25
EP2309985A2 (en) 2011-04-20
CA2732243C (en) 2016-11-29
CA2732243A1 (en) 2010-02-04
US20130261156A1 (en) 2013-10-03
CR20110110A (en) 2011-04-28
JP2011529445A (en) 2011-12-08
PE20141585A1 (en) 2014-11-13
EA201170272A1 (en) 2011-10-31
CL2011000170A1 (en) 2011-06-10
BRPI0916689A2 (en) 2015-11-17
CN102743330A (en) 2012-10-24
NZ591344A (en) 2013-03-28
MY169461A (en) 2019-04-11
WO2010013823A3 (en) 2010-04-15
JP5593363B2 (en) 2014-09-24
DOP2013000172A (en) 2013-11-15
US9186411B2 (en) 2015-11-17
CN104784180A (en) 2015-07-22
EP2564833A1 (en) 2013-03-06
GEP20146122B (en) 2014-07-25
CA2936400A1 (en) 2010-02-04
CO6290638A2 (en) 2011-06-20
JP2013047239A (en) 2013-03-07
ECSP11010855A (en) 2011-03-31
EA201201451A1 (en) 2013-07-30
EP2309985B1 (en) 2018-03-14
CN102164581A (en) 2011-08-24
CA2936400C (en) 2018-03-27

Similar Documents

Publication Publication Date Title
PE20140977A1 (en) PHARMACEUTICAL COMPOSITION STABILIZED BASED ON A NON-PEPTIDIC COMPOUND
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
PE20051094A1 (en) DERIVATIVES OF 7-PHENYLAMINE-4-QUINOLONE-3-CARBOXYL ACID AND PROCESSES FOR ITS PREPARATION
PE20141552A1 (en) PHARMACEUTICAL COMPOSITIONS
PE20081882A1 (en) USEFUL PYRIDAZINONE DERIVATIVES AS GLUCAN SYNTHASE INHIBITORS
AR075139A1 (en) BICYCLE COMPOUNDS FOR THE REDUCTION OF BETA-AMILOID PRODUCTION
CO5690607A2 (en) PIRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA IV
ECSP10010060A (en) SUBSTITUTED PIRAZOL DERIVATIVES
PE20201165A1 (en) PYRIDAZINE 1,4-DISUSTITUTED ANALOGS AND METHODS FOR TREATING CONDITIONS RELATED TO SMN DEFICIENCY
HUP0401784A2 (en) Viral polymerase inhibitors with a heterobicyclic structure, process for their preparation, their intermediates and pharmaceutical compositions containing them
EA201170772A1 (en) ORGANIC COMPOUNDS
ECSP099638A (en) NEW ADENINE COMPOUND
CO6612278A2 (en) Aqueous antiperspirant / deodorant composition
CO6180507A2 (en) DERIVED FROM 2-PYRIDINCARBOXAMIDE THAT HAS GK ACTIVATING EFFECT
EA201270216A1 (en) PHARMACEUTICAL COMPOSITION
AR070117A1 (en) PIRIDILAMIDINE COMPOSITE OR ITS SALT, AND COMPOSITION FUNGICIDA AGRICOLA OR HORTICOLA CONTAINING IT AS ACTIVE INGREDIENT
PE20120648A1 (en) 4-ISOPROPYLPHENYLGLUCITOL COMPOUNDS AS SGLT1 INHIBITORS
CO6341610A2 (en) AROMATIC HETEROCICLYL COMPOUND CONTAINING NITROGEN.
ES2545810T3 (en) Process to stabilize the bacterial content of aqueous mineral preparations comprising ground natural calcium carbonate and / or precipitated calcium carbonate and / or dolomite and / or surface reacted calcium carbonate
PE20081700A1 (en) PIRANONE ACID DERIVATIVES SUBSTITUTED AS AGENTS TO TREAT METABOLIC SYNDROME
AR073043A1 (en) COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS.
PE20091079A1 (en) HETEROCYCLIC COMPOUNDS AS NPY Y2 MODULATORS
MX2009008028A (en) Benzofuran antiparasitic agents.
PE20130179A1 (en) NEW TERTIARY DERIVATIVES OF 8-HYDROXYQUINOLINE-7-CARBOXAMIDE
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics

Legal Events

Date Code Title Description
FA Abandonment or withdrawal